QuidelOrtho (NASDAQ:QDEL) Releases FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.070-2.570 for the period, compared to the consensus earnings per share estimate of 2.380. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.7 billion.

QuidelOrtho Stock Down 2.0%

Shares of NASDAQ QDEL opened at $28.11 on Thursday. The stock has a market capitalization of $1.90 billion, a P/E ratio of -5.66 and a beta of 0.10. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.66 and a current ratio of 1.20. The stock’s fifty day moving average is $29.64 and its 200 day moving average is $36.17. QuidelOrtho has a 52 week low of $23.77 and a 52 week high of $49.45.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.13. The company had revenue of $692.80 million for the quarter, compared to analyst estimates of $694.97 million. QuidelOrtho had a negative net margin of 12.07% and a positive return on equity of 4.71%. The company’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.44 EPS. Sell-side analysts forecast that QuidelOrtho will post 2.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QDEL has been the topic of several recent analyst reports. Wall Street Zen raised shares of QuidelOrtho from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. Jefferies Financial Group upgraded QuidelOrtho from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Thursday, May 8th. UBS Group reduced their price objective on shares of QuidelOrtho from $45.00 to $29.00 and set a “neutral” rating for the company in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of QuidelOrtho from $38.00 to $25.00 and set an “underweight” rating on the stock in a research note on Monday, April 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.33.

Institutional Investors Weigh In On QuidelOrtho

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of QuidelOrtho by 1,218.7% during the 1st quarter. Royal Bank of Canada now owns 80,193 shares of the company’s stock valued at $2,803,000 after buying an additional 74,112 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of QuidelOrtho by 10.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company’s stock worth $7,987,000 after acquiring an additional 21,968 shares in the last quarter. Finally, Focus Partners Wealth raised its stake in shares of QuidelOrtho by 210.9% during the first quarter. Focus Partners Wealth now owns 20,454 shares of the company’s stock worth $715,000 after acquiring an additional 13,876 shares in the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.